BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS
NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the ... Read More
China’s CF PharmTech raises $50m in Series F round for inhalation products
CF PharmTech, a Chinese pharma company, has raised $50 million in a Series F financing round to accelerate the commercialization of its inhalation products. The ... Read More
China’s CF PharmTech raises $50m in Series F round for inhalation products
CF PharmTech, a Chinese pharma company, has raised $50 million in a Series F financing round to accelerate the commercialization of its inhalation products. The ... Read More
Noxopharm launches NOXCOVID-1 clinical trial of Veyonda across Europe
Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as ... Read More
India-based Piramal Pharma secures $490m investment from Carlyle Group
The Carlyle Group has signed a deal worth around $490 million with Piramal Enterprises, to acquire a stake of 20% from the Indian conglomerate's pharma ... Read More
Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial
Covid-19 stem cell clinical trial : Celltex Therapeutics has been given the clearance by the US Food and Drug Administration (FDA) to move ahead with ... Read More
Masimo gets FDA clearance for Centroid patient monitoring sensor
Masimo, a US medical device company, has received clearance from the US Food and Drug Administration (FDA) for Centroid, the company's wearable, wireless patient orientation, ... Read More
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More
Yumanity secures $500m worth deal with Merck to develop therapies for neurodegenerative disorders
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative ... Read More
Zogenix bags Fintepla FDA approval for Dravet syndrome treatment
Fintepla FDA approval : Zogenix has bagged approval from the US Food and Drug Administration (FDA) for Fintepla (fenfluramine) oral solution, CIV for the treatment ... Read More